Home › Novartis agrees to sell its flu vaccine business to CSL of Australia for $275 million
 

Keywords :   


Novartis agrees to sell its flu vaccine business to CSL of Australia for $275 million

2014-10-27 22:24:44| Biotech - Topix.net

CSL Ltd. said the deal will make it the second-largest flu vaccine maker in the world. The company said the Novartis business had $527 million in revenue in 2013 and said its combined revenue could reach $1 billion a year in three to five years.

Tags: business sell australia million

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Public Advisory Number 18A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Eastern North Pacific Tropical Weather Outlook
03.07Atlantic Tropical Weather Outlook
03.07Benefits of benchmarking in the pork industry
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Forecast Discussion Number 18
More »